Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T12:50:30.304Z.
Calculation as of: 2026-10-06T12:50:30.304Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b8bc85e2d5351a47333dd9131f39a7cf6b6d5f02586c5202dd123a5ad4370615
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$108.39M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$111.17M
Price/FCF Ratio
N/A
TTM Avg
8.08
3Y Avg
8.08
5Y Avg
8.08
Market Cap
$106.23M
Price/FCF Ratio
N/A
TTM Avg
23.61
3Y Avg
13.61
5Y Avg
10.78
Market Cap
$114.24M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$104.07M
Price/FCF Ratio
3.64
TTM Avg
4.64
3Y Avg
13.17
5Y Avg
35.61
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Apyx Medical Corporation (APYX) | $109.49M | N/A | N/A | N/A | N/A |
| Immunic, Inc. (IMUX)vs › | $109.93M | N/A | N/A | N/A | N/A |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $108.39M | N/A | N/A | N/A | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $111.17M | N/A | 8.08 | 8.08 | 8.08 |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.23M | N/A | 23.61 | 13.61 | 10.78 |
| Coya Therapeutics, Inc. (COYA)vs › | $113.77M | N/A | N/A | N/A | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $114.24M | N/A | N/A | N/A | N/A |
| Definitive Healthcare Corp. (DH)vs › | $104.07M | 3.64 | 4.64 | 13.17 | 35.61 |
| Genelux Corporation (GNLX)vs › | $116.59M | N/A | N/A | N/A | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $117.43M | N/A | 1.66 | 1.66 | 1.66 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
